Clinical trials: Bone Marrow
Paroxysmal Nocturnal Hemoglobinuria
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837…
- Trial name
- NCT07747090
- Testing
- FXS6837 Capsule, Eculizumab infusion
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Myelodysplastic Syndrome
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
The purpose of this randomized, double-blind, placebo-controlled study is to determine the safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and FDA approved treatment for Myelodysplastic…
- Trial name
- NCT01873703
- Testing
- pracinostat, Azacitidine
- Where
- 24 sites in United States
- Volunteers
- 102 people
- Sponsor
- Helsinn Healthcare SA
Anemia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a…
- Trial name
- MDS-005 (NCT01029262)
- Testing
- Lenalidomide
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 239 people
- Sponsor
- Celgene
Relapsed / Refractory Myelodysplastic Syndromes
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes
- Trial name
- NCT05371730
- Testing
- NCR300
- Volunteers
- 15 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Polycythemia Vera, Essential Thrombocythemia
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK)…
- Trial name
- NCT01998828
- Testing
- Momelotinib
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 39 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation…
- Trial name
- NCT05153343
- Testing
- flonoltinib 25mg, flonoltinib 100mg, flonoltinib 150mg
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the…
- Trial name
- NCT02058277
- Testing
- bosutinib or bosutinib + aprepitant
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.
- Trial name
- NCT06932744
- Testing
- MY008211A tablets, Eculizumab Injection
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Pure Red-Cell Aplasia, Chronic Kidney Failure
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate…
- Trial name
- PRIMS (NCT00391287)
- Where
- 387 sites in Australia, Belgium and 13 more
- Volunteers
- 15,334 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myelofibrosis
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
This was an open-label, multi-center, randomized phase 2 study. This is a two-stage design.In the first stage, two dose groups were set up, the 100 mg bid dose group and the 200 mg qd dose group, which were randomized at 1:1…
- Trial name
- NCT03886415
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-Ischemic Heart Failure
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
- Trial name
- NCT02467387
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer's Solution
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- CardioCell LLC
Leukemia, Acute Myeloid Leukemia
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
- Conditions
- Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05061147
- Testing
- MAX-40279-01
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Maxinovel Pty., Ltd.
Non-Hodgkin's Lymphoma
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
The purpose of this study is to determine the proper dose, effectiveness, and safety of using Iodine-131 Anti-B1 Antibody for the treatment of patients with previously treated non-Hodgkin's lymphoma (NHL) who have greater than…
- Trial name
- NCT00022906
- Testing
- Iodine-131 Anti-B1 Antibody
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Corixa Corporation
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04884191
- Testing
- Pacritinib
- Where
- 62 sites in United States, France and 6 more
- Volunteers
- 165 people
- Sponsor
- CTI BioPharma
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- Simplify 2 (NCT02101268)
- Testing
- Momelotinib, Best Available Therapy (BAT)
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Myelodysplastic Syndromes
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome
The purpose of this study is to investigate the overall response rate (ORR) and safety when treating patients with myelodysplastic syndrome with decitabine.
- Trial name
- NCT01400633
- Testing
- decitabine injection
- Where
- 16 sites in South Korea
- Volunteers
- 156 people
- Sponsor
- Janssen Korea, Ltd., Korea
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.